Proceeds will be used to advance Casma’s First-in-Class TRPML1 agonist in muscular dystrophy and enable preclinical proof-of-concept for the Company’s novel autophagy degrader platform CAMBRIDGE, Mass., September 10, 2020-- Casma Therapeutics, Inc., a biotechnology company harnessing autophagy and the lysosome to design powerful new medicines, today announced the completion of a $50 million Series B financing. The financing, led by The Column Group (TCG), adds new investors Eventide Asset Management, LLC and Schroder Adveq, as well as other undisclosed institutional investors. Existing investor Third Rock Ventures also participated in the Series B.